These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19015652)

  • 1. What advice should be given to patients with NAFLD about the consumption of alcohol?
    Sozio MS; Chalasani N; Liangpunsakul S
    Nat Clin Pract Gastroenterol Hepatol; 2009 Jan; 6(1):18-9. PubMed ID: 19015652
    [No Abstract]   [Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes.
    Birkenfeld AL; Shulman GI
    Hepatology; 2014 Feb; 59(2):713-23. PubMed ID: 23929732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diabetes and the liver].
    Herzig S; Roden M
    Dtsch Med Wochenschr; 2013 Jun; 138(23):1204-6. PubMed ID: 23720171
    [No Abstract]   [Full Text] [Related]  

  • 4. Relationship between fatty liver and glucose metabolism: a cross-sectional study in 571 obese children.
    Bedogni G; Gastaldelli A; Manco M; De Col A; Agosti F; Tiribelli C; Sartorio A
    Nutr Metab Cardiovasc Dis; 2012 Feb; 22(2):120-6. PubMed ID: 20880682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic Fatty liver disease is associated with increased carotid intima-media thickness only in type 2 diabetic subjects with insulin resistance.
    Kim SK; Choi YJ; Huh BW; Park SW; Lee EJ; Cho YW; Huh KB
    J Clin Endocrinol Metab; 2014 May; 99(5):1879-84. PubMed ID: 24512497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people.
    Ikai E; Ishizaki M; Suzuki Y; Ishida M; Noborizaka Y; Yamada Y
    J Hum Hypertens; 1995 Feb; 9(2):101-5. PubMed ID: 7752170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Alcohol, metabolic syndrome and obesity: impact on treatment efficacy].
    Serfaty L; Mathurin P; Cadranel JF; Tran A
    Gastroenterol Clin Biol; 2007; 31(8-9 Pt 3):4S40-3. PubMed ID: 17965634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial).
    Bacchi E; Negri C; Targher G; Faccioli N; Lanza M; Zoppini G; Zanolin E; Schena F; Bonora E; Moghetti P
    Hepatology; 2013 Oct; 58(4):1287-95. PubMed ID: 23504926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on nonalcoholic fatty liver disease.
    McCullough AJ
    J Clin Gastroenterol; 2002 Mar; 34(3):255-62. PubMed ID: 11873108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
    Cusi K
    Gastroenterology; 2012 Apr; 142(4):711-725.e6. PubMed ID: 22326434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel insights into the pathophysiology of nonalcoholic fatty liver disease.
    Feldstein AE
    Semin Liver Dis; 2010 Nov; 30(4):391-401. PubMed ID: 20960378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.
    Marchesini G; Brizi M; Bianchi G; Tomassetti S; Bugianesi E; Lenzi M; McCullough AJ; Natale S; Forlani G; Melchionda N
    Diabetes; 2001 Aug; 50(8):1844-50. PubMed ID: 11473047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease and cardiovascular risk.
    Brea A; Puzo J
    Int J Cardiol; 2013 Aug; 167(4):1109-17. PubMed ID: 23141876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin resistance in nonalcoholic fatty liver disease.
    Bugianesi E; Moscatiello S; Ciaravella MF; Marchesini G
    Curr Pharm Des; 2010 Jun; 16(17):1941-51. PubMed ID: 20370677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ectopic fat, insulin resistance and non-alcoholic fatty liver disease.
    Byrne CD
    Proc Nutr Soc; 2013 Nov; 72(4):412-9. PubMed ID: 23668723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatty liver: a novel component of the metabolic syndrome.
    Kotronen A; Yki-Järvinen H
    Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):27-38. PubMed ID: 17690317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinol-binding protein 4 and new adipocytokines in nonalcoholic fatty liver disease.
    Tönjes A; Blüher M; Stumvoll M
    Curr Pharm Des; 2010 Jun; 16(17):1921-8. PubMed ID: 20370670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association of obesity, metabolic syndrome, diabetes, and cardiovascular disease with nonalcoholic fatty liver disease.
    Bell DS
    South Med J; 2009 Oct; 102(10):991-2. PubMed ID: 19738529
    [No Abstract]   [Full Text] [Related]  

  • 19. Fatty liver: cause or consequence.
    Hitman GA
    Diabet Med; 2012 Sep; 29(9):1097. PubMed ID: 22882641
    [No Abstract]   [Full Text] [Related]  

  • 20. Short-term abstinence from alcohol and changes in cardiovascular risk factors, liver function tests and cancer-related growth factors: a prospective observational study.
    Mehta G; Macdonald S; Cronberg A; Rosselli M; Khera-Butler T; Sumpter C; Al-Khatib S; Jain A; Maurice J; Charalambous C; Gander A; Ju C; Hakan T; Sherwood R; Nair D; Jalan R; Moore KP
    BMJ Open; 2018 May; 8(5):e020673. PubMed ID: 29730627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.